Abstract
We previously reported two patients with metastatic colorectal adenocarcinoma who, after referral to the precision medicine tumour board, had tissue and longitudinal liquid biopsies and responded to targeted therapy based on their molecular profile. These patients are from the SCRUM-MONSTAR programme, a nationwide genome-screening project in Japan that is part of the International Cancer Genome Consortium–Accelerating Research in Genomic Oncology. Here, we summarise the clinical history of the two patients and report an update on clinical course and longitudinal molecular assessment using circulating-tumour DNA (ctDNA) sequencing.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
